(Q52423311)

English

A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.

scientific article published in January 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

author name string

P Jakobsen

1

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

L Bastholt

2

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

M Dalmark

3

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

P Pfeiffer

4

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

D Petersen

5

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

S B Gjedde

6

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

E Sandberg

7

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

C Rose

8

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

O S Nielsen

9

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

H T Mouridsen

10

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

publication date

1 January 1991

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

28

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

6

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

465-469

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

https://scigraph.springernature.com/pub.10.1007/bf00685824

0 references

Anthracycline pharmacokinetics. Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin)

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative pharmacokinetic study of adriamycin and 4'epi-adriamycin after their simultaneous intravenous administration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sensitive and specific determination of the new anthracycline analog 4'-epidoxorubicin and its metabolites by high pressure liquid chromatography

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dependence of the cytostatic effect of adriamycin on drug concentration and exposure time in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00685824

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 May 2018

http://europepmc.org/abstract/MED/1934250

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52423311&oldid=1380579263"